However, considering that ERK activation in the MAPK pathway promotes both tumor growth and T cell proliferation, and that anti-CTLA4 agents can cause uveitis as a rare side effect, it has been suggested that BRAF inhibitors may induce uveitis through a similar mechanism by activating ERK in certain patients [70]. This evidence concerns the gene CTLA4 and neoplasm.